FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs lifted their FY2024 earnings estimates for shares of Zentalis Pharmaceuticals in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($2.68) per share for the year, up from their prior forecast of ($3.05). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($1.01) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.39) EPS and FY2027 earnings at ($3.14) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36.

Other research analysts have also issued reports about the stock. Guggenheim cut their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price for the company in a research report on Monday, August 12th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $3.05 on Monday. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07. The firm has a fifty day moving average of $3.42 and a 200 day moving average of $5.33. The firm has a market capitalization of $217.34 million, a PE ratio of -1.22 and a beta of 1.74.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Anfield Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at about $40,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Finally, Capstone Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.